Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that MSI-H status confers therapeutic sensitivity to Pembrolizumab in patients with Any solid tumor.
This statement is based on a regulatory approval from the Health Canada:
KEYTRUDA (pembrolizumab) is indicated as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.